Boehringer In­gel­heim’s obe­si­ty as­set sur­vo­du­tide, which it li­censed from Zealand Phar­ma, has shown high rates of dis­con­tin­u­a­tions in its Phase 3 obe­si­ty study.

In April...

The long-act­ing GLP-1 shot that was the cen­ter­piece of Pfiz­er’s ac­qui­si­tion of Met­sera last year looks ef­fec­tive in pa­tients with both obe­si­ty and di­a­betes, ac­cord­ing...

A dai­ly in­cretin shot be­ing de­vel­oped by Roche has shown promise in type 1 di­a­betes — the form that is not gen­er­al­ly be­lieved to be...

Roche says it has one obe­si­ty drug with a po­ten­tial best-in-class safe­ty pro­file, and an­oth­er with a sim­i­lar shot at lead­ing in ef­fi­ca­cy. Com­bin­ing them...